Bernstein’s 34th Annual Strategic Decisions Conference
Mike Mahoney
Chairman and Chief Executive Officer
Bernsteins 34 th Annual Strategic Decisions Conference Mike Mahoney - - PowerPoint PPT Presentation
Bernsteins 34 th Annual Strategic Decisions Conference Mike Mahoney Chairman and Chief Executive Officer Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of
Chairman and Chief Executive Officer
2
This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or
materially from the expectations and projections expressed or implied by our forward-looking statements. Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings “Risk Factors” and “Safe Harbor for Forward-Looking Statements.” Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. Non-GAAP Measures: This document contains non-GAAP measures (denoted with *) in talking about our company’s performance. The reconciliations of those non-GAAP measures to their most comparable GAAP measures are contained within this document including appendices attached to the end of this presentation. Financial Disclaimers: Operational growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations. Organic growth rates are non- GAAP measures that exclude the impact of changes in foreign currency exchange rates and the sales from significant acquisitions (Symetis SA, the American Medical Systems male urology portfolio and EndoChoice Holdings, Inc.) in the relevant periods. We define Emerging Markets as including certain countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Currently, we have 20 countries in our definition of Emerging Markets. Market Estimates: Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates.
3
Product Regulatory Disclaimer Implantable Cardiac Monitor Device under development. Not available for use or sale worldwide. EMPOWER™ Leadless Pacer Device under development. Not available for use or sale worldwide. Apama RF Balloon Catheter Device under development. Not available for use or sale worldwide. DrectSense™ Technology Device under development. Not available for use or sale worldwide. Ranger™ Drug-Coated Balloon CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale. Drug Eluting Stent – Below-the-knee indication Device under development. Not available for use or sale worldwide. Eluvia™ Drug eluting self-expanding SFA stent CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale. Lotus Edge™ U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale. ACURATE™ Self Expanding Valve Platform CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale. WATCHMAN™ FLX Pending CE Mark. Not available for use or sale in the U.S.
4
Caring Meaningful Innovation High Performance Global Collaboration Diversity Winning Spirit
5
and a “WINNING SPIRIT”
economic value drivers
increase patient access
large & high growth markets
portfolio & capabilities
top tier of peer group
EPS CAGR +14.5%
CAGR +DD
allocation strategy: more to come
cumulative in years 2018-2020
6
$0.3B, +14%
2017 Revenue and Operational Growth*: (Total company: $9.0B, 8%; Organic Growth* 7%) Rhythm Management Interventional Cardiology Structural Heart Peripheral Interventions
$2.4B, +6% $1.1B, +7% $275M+
CRM Electrophysiology
$1.9B, +2%
Endoscopy Urology & Pelvic Health Neuromodulation
$1.6B, +12% $0.6B, +14% $1.1B, +12%
7
Reported Revenue, Y/Y Operational* growth Y/Y Organic* growth rates
18.9% 20.2% 22.3% 24.1%
2013 2014 2015 2016 2017
$7.1 $7.4 $7.5 $8.4 $9.0
2013 2014 2015 2016 2017
+2% +6% +8% +12% +8% +4% +5% +10% +7%
$0.73 $0.84 $0.93 $1.11
2013 2014 2015 2016 2017
+11% +15% +11% +20% +13%
$1.26
Sales growth consistently > mkt w/ avg. 7% organic* growth ’15-’17E Delivering on margin expansion goals Consistent double digit adj. EPS* growth: 14.5% CAGR ’15-’17
25.0%
8
Estimated Market Growth Rates
Low Growth 35% Moderate Growth 50% Low Growth 46% Moderate Growth 47%
2017 Revenue Mix $9.0B 2020E Revenue Mix 2012 Revenue Mix $7.2B
High Growth Mkt (10%+ CAGR): SCS, TAVR, LAAC, EP, DBS, PI Drug Eluting, ICM
High Growth 7% High Growth 15%
Low Growth 25% Moderate Growth 50% High Growth 25%
Low Growth Mkt (0 - 3% CAGR): Pacers, Defibrillators, DES Moderate Growth Mkt (4 - 9% CAGR): Endo, UroPH, PI (ex DES & DCB), Int. Oncology, IC (ex. SH, DES)
9
Coronary Therapies
Structural Heart
U.S./Japan
expansion
Peripheral Interventions
CRM/EP
Neuromodulation
Endo
U.S./EU
Urology/Pelvic Health
Coronary Therapies
Structural Heart
expansion
EU Peripheral Interventions
CRM/EP
Neuromodulation
Endo
gen
Urology/Pelvic Health
Coronary Therapies
Structural Heart
Expansion
PI
CRM/EP
LUMIPOINTTM
Neuromodulation
Endoscopy
(valves, kits)
cholangioscopy tools
Urology/Pelvic Health
**Intend to launch Lotus in the U.S. & EU in 2019 pending final testing & regulatory approvals All launches are WW, unless otherwise noted
10
2013 2014 2015 2016 2017 2020E
25.0% 24.1% 30+% 22.3% 20.2% 18.9%
~+300 bps
SG&A productivity Accretive new products Launches & commercial scale of key products R&D efficiencies 5-10% annual standard cost improvements
28%
Longer Term Goal
11
Strong Free Cash Flow*: 2016- 2020E Improved Ability to Deploy Cumulative Free Cash Flow*
** Based on adjusted free cash flow. Refer to non-GAAP reconciliations
2015-2017: ~$4.7B 2018E-2020E: ~$6.3B
10%
Reserved Contingencies** M&A or Returning Cash to Shareholders
20% 10%
2016 2017 2018E 2019E 2020E $1.6B $1.7B ~$1.9B ~$2.1B ~$2.3B
12
Venture Portfolio Tuck-in M&A Pipeline
2011 - 2012 - 2013 - 2014 - 2015 - 2016 - 2017 - 2018
Peripheral Vasc. LumenR
Portfolio of 30+ Companies in Selected Spaces:
Securus Medical Group
13
✓ Tax court dispute concluded for tax years 2001 – 2010 ✓ Exploring ways to reinvest this one-time non-GAAP benefit into our LT tax structure
✓ Expect to resolve tax years 2011 – 2013 before YE 2018 on the same basis
Net payments expected to be
expected to be made within 3 months
One-time, non-cash adj. tax benefit of $70-80M to be recorded in Q2 No impact to our 2018 estimated annual adjusted ETR
benefit in Q3 and Q4
time, non-cash benefit is $225-250M
based on how reserves were originally booked
see variability in quarterly tax rates
2018 full-year adjusted EPS guidance
14
Recognized for progressive life/work policies and programs Ranked #35 based on employee ratings Ranked #16 in the U.S. Ranked #3 on U.S. Large Company list Scored 100% for the 4th consecutive year Scored 100% for the 2nd year in a row Highest recognition for Guard/Reserve employee support Ranked 6th in industry category
15
16
17
18
Adjusted Free Cash Flow (in millions) Cumulative 2015-2017ꝉ 2017 2016ꝉ 2015ꝉ Operating Cash Flow, as reported $ 3,299 $ 1,426 $ 1,182 $ 691 Plus: Proceeds on disposals of property, plant and equipment 29
942 319 376 247 Free Cash Flow 2,386 1,107 835 444 Plus: Restructuring Payments 248 72 81 95 Plus: Earnouts 128 14 57 57 Plus: Special Tax Refunds/Credits (387) (239) (74) (74) Plus: Legal Settlements 2,148 694 701 753 Plus: Other 194 81 22 91 Adjusted Free Cash Flow $ 4,717 $ 1,729 $ 1,622 $ 1,366 ꝉ - Certain prior year balances within our Consolidated Statement of Cash Flow have been updated to reflect the adoption of ASC Update 2016-15 and ASC Update 2016-18. Please refer to our annual report on Form 10-K for the period ended December 31, 2017 for additional details. Adjusted Free Cash Flow (in billions) Cumulative 2018E-2020Eꝉ 2020Eꝉ 2019Eꝉ 2018Eꝉ Operating Cash Flow, estimated GAAP $ - $ - $ - $ - Plus: Proceeds on disposals of property, plant and equipment
$ 6.3 $ 2.3 $ 2.1 $ 1.9 ꝉ - Components of the reconciliation of operating cash flow, as reported, are not currently available.
19
FY2017 Net Sales Growth as compared to FY2016 As Reported Less: Impact of Foreign Currency Operational* Less: Impact of Significant Acquisitions Organic* Interventional Cardiology 6.2% 0.1% 6.1% Peripheral Interventions 6.5%
6.6% Cardiovascular 6.3% 0.0% 6.3% Cardiac Rhythm Management 2.5% 0.2% 2.3% Electrophysiology 14.5% 0.1% 14.4% Rhythm Management 3.9% 0.2% 3.7% Endoscopy 12.4% 0.1% 12.3% Urology & Pelvic Health 11.8% 0.2% 11.6% Neuromodulation 14.2% 0.1% 14.1% MedSurg 12.5% 0.1% 12.4% Total Company 7.9% 0.1% 7.8% 1.2% 6.6%
20
The following is an explanation of the adjustments that management excluded from GAAP measures to calculate the following forward-looking non-GAAP financial measures: Adjusted Gross Margin: Excludes from GAAP gross margin the impacts of forecasted acquisition- and divestiture- and restructuring-related charges or credits. Adjusted SG&A: Excludes from GAAP SG&A the impacts of forecasted acquisition- and divestiture- and restructuring-related charges or credits. Adjusted R&D: Excludes from GAAP R&D the impacts of forecasted acquisition- and divestiture- and restructuring-related charges or credits. Adjusted Operating Margin: Excludes from GAAP operating margin the impacts of forecasted acquisition- and divestiture- and restructuring- and restructuring-related charges or credits, and amortization expense. Adjusted Tax Rate: Excludes from GAAP tax rate the tax impacts related to forecasted acquisition- and divestiture- and restructuring- and restructuring-related charges or credits, and amortization expense. Adjusted Free Cash Flow: Adjusts GAAP operating cash flow to include the impacts of forecasted capital expenditures and excludes the impact of estimated after-tax acquisition- and divestiture-, restructuring- and litigation-payments. Please refer to our Safe Harbor for forward-looking statements disclosure in conjunction with any forward looking information presented within.